Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Deals Update, September 2014

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced in late July-September 2014.

You may also be interested in...



Device Debuts: Medtronic, Boston Scientific, Philips, Seventh Sense, Vortex, 410 Medical

Device Debuts is a new regular feature highlighting Medtech Insight editors’ top picks of medical devices that have been commercialized for the first time in the last month. This edition features an innovative minimally invasive surgical stapler, a pain-free blood-collection device, a novel approach for collecting, and circulating tumor cells, a rapid fluid-infusion device for critically ill patients, and an EP-mapping and navigation system.

US FDA Announces Update To Recognized Standards List

The national and international standards can be used during the device assessment process.

Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

Topics

Related Companies

UsernamePublicRestriction

Register

MT035820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel